Cardiovascular risk optimisation in endometrial cancer survivors
Research type
Research Study
Full title
OPtimising cardiovascular healTh In endoMetrial cancer sUrvivorS (OPTIMUS study)\n
IRAS ID
298610
Contact name
Emma Crosbie
Contact email
Sponsor organisation
University of Manchester
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Women successfully treated for endometrial cancer remain at higher risk of dying than women without a history of the disease, predominately due to an excess risk of cardiovascular disease. Our previous work has shown that endometrial cancer survivors are more likely to have undiagnosed and undertreated cardiovascular risk factors than the general population, despite being seen regularly by medical professionals. This study aims to determine the impact of optimising modifiable cardiovascular risk factors in endometrial cancer survivors on their quality of life and to identify barriers to lifestyle modifications.\n\nA comprehensive cardiovascular risk assessment will be performed as part of clinical care on women previously treated for endometrial cancer at the study site and will include a focussed interview, examination to determine body mass, blood test and urine sample. Based on these findings, an individualised management plan will be generated and appropriate treatment for any modifiable risk factors commenced in accordance with NICE guidance. Women will be followed up over a one year period to monitor their response and compliance to treatment and the impact this has on their quality of life. Study visits will be timed to coincide with routine follow-up appointments or be carried out remotely by telephone or Zoom to minimise the risk of COVID-19 exposure. Follow-up visits will consist of a focussed interview and quality of life questionnaires. A small subset of women will also undergo more detailed interviews to identify any barriers to making lifestyle modifications. \n
REC name
South Central - Oxford B Research Ethics Committee
REC reference
21/SC/0371
Date of REC Opinion
18 Nov 2021
REC opinion
Further Information Favourable Opinion